Odyssey Therapeutics Reports Positive Clinical Proof-of-Concept for Lead Candidate OD-001 and Strong Cash Runway
ODTX sits 16% above its 52-week low of $16.
Summary
Odyssey Therapeutics reported strong clinical proof-of-concept data for its lead drug candidate, OD-001, in ulcerative colitis, alongside a healthy cash balance expected to fund operations into late 2028.
Key Events · Product Development and Regulatory · ODTX
-
Positive Clinical Proof-of-Concept for OD-001
Lead candidate OD-001 achieved clinical proof-of-concept in a Phase 2a trial for moderate to severe ulcerative colitis, showing 27% clinical remission and 61% clinical response. The drug was well tolerated.
-
Extended Cash Runway
The company reported a pro-forma cash position of $464.4 million as of March 31, 2026, which is expected to fund operations into the second half of 2028.
-
Q1 2026 Financial Results
Reported a net loss of $38.3 million for the first quarter ended March 31, 2026, with R&D expenses at $32.3 million.
-
Upcoming Clinical Milestones
Plans to initiate Phase 2b monotherapy and Phase 2a combination trials for OD-001 in H2 2026, with topline data expected in H2 2027. Also plans to file a CTA for OD-002 in H2 2026.
Analysis · ODTX · Life Sciences
Odyssey Therapeutics announced positive clinical proof-of-concept data for its lead candidate, OD-001, in a Phase 2a trial for ulcerative colitis. This de-risks the program significantly, showing efficacy with 27% clinical remission and 61% clinical response. The company also reported a robust cash position of $464.4 million, extending its operational runway into the second half of 2028, which provides financial stability for advancing its pipeline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ODTX was trading at $18.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $871.8M. The 52-week trading range was $16.00 to $18.72. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.